App Store

Google Play

BG - Details page - Device banner - 894x1036

Открийте безкрайна вселена от истории

Слушайте и четете

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The second volume of this series features 7 reviews presenting updates on hormones and several classes of drugs:

Osteocalcin action in glucose metabolism
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Glucagon-like peptide-1 (GLP-1) mimetics
Dipeptidyl peptidase 4 (DPP-4) inhibitors
New drugs in clinical trial and commercial phases

Bentham Science

Frontiers in Clinical Drug Research - Diabetes and Obesity

Frontiers in Clinical Drug Research - Diabetes and Obesity: Volume 2

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The fourth volume of this series features 7 chapters:

-Pharmacologic Obesity Treatment

-Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic Complications

-Sodium–Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus

-The Effects of Traditional Chinese Medicine on Inflammatory Cytokines in Diabetic Nephropathy

-Through the Perspective of Histology – The Alzheimer’s Disease Promotion by Obesity and Glucose Metabolism: Type 3 Diabetes

-Pharmacological Mechanism of PPARγ Ratio in Diabetes and Obesity

-Hydrogen Sulfide and Carbohydrate Metabolism

Frontiers in Clinical Drug Research - Diabetes and Obesity: Volume 4

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The fifth volume of this series features 5 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist.

-Metabolic syndrome in schizophrenia

-Insulin therapy and foetoplacental endothelial dysfunction in gestational diabetes mellitus

-Insights on diabetes, oxidative stress and antioxidant therapeutic strategies

-Administration of nano drugs in the treatment of diabetes mellitus

-SGLT-2 inhibitors

Frontiers in Clinical Drug Research: Diabetes and Obesity: Volume 5

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The sixth volume of this series features 6 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist. - The failing heart in diabetes with special emphasis on prevention- Flavonoids as prominent anti-diabetic agents- Chemosensor in glucose monitoring, advances and challenges - Synergistic drugs and polyherbal formulations for obesity: current status and future prospectives- Urge for herbal anti-diabetic medicines towards clinical and therapeutic implications- Curcuma longa as a dietary supplement and medication for diabetes mellitus: evidence from experimental studies